Catalase activity and arsenic sensitivity in acute leukemia

References

• Soignet S L, Maslak P, Wang Z G, Jhanwar S, Calleja E, Dardashti L J, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348
   PubMed Web of Science ®Google Scholar
• Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860
   PubMed Web of Science ®Google Scholar
• Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627–2632
   PubMed Web of Science ®Google Scholar
• Duprez E, Saurin A J, Desterro J M, Lallemand-Breitenbach V, Howe K, Boddy M N, et al. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 1999; 112: 381–393
   PubMed Web of Science ®Google Scholar
• Kamitani T, Kito K, Nguyen H P, Wada H, Fukuda-Kamitani T, Yeh E T. Identification of three major sentrinization sites in PML. J Biol Chem 1998; 273: 26675–26682
   PubMedGoogle Scholar
• Amadori S, Fenaux P, Ludwig H, O'Dwyer M, Sanz M. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 2005; 21: 403–411
   PubMed Web of Science ®Google Scholar
• Kumana C R, Au W Y, Lee N S, Kou M, Mak R W, Lam C W, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 2002; 58: 521–526
   PubMed Web of Science ®Google Scholar
• Parmar S, Rundhaugen L M, Boehlke L, Riley M, Nabhan C, Raji A, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 2004; 28: 909–919
   PubMed Web of Science ®Google Scholar
• Chen Y C, Lin-Shiau S Y, Lin J K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998; 177: 324–333
   PubMed Web of Science ®Google Scholar
• Kong Q, Beel J A, Lillehei K O. A threshold concept for cancer therapy. Med Hypotheses 2000; 55: 29–35
   PubMed Web of Science ®Google Scholar
• DiPietrantonio A M, Hsieh T, Wu J M. Activation of caspase 3 in HL-60 cells exposed to hydrogen peroxide. Biochem Biophys Res Commun 1999; 255: 477–482
   PubMed Web of Science ®Google Scholar
• Girotti A W. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998; 39: 1529–1542
   PubMed Web of Science ®Google Scholar
• Sheabar F Z, Yannai S. In vitro effects of cadmium and arsenite on glutathione peroxidase, aspartate and alanine aminotransferases, cholinesterase and glucose-6-phosphate dehydrogenase activities in blood. Vet Hum Toxicol 1989; 31: 528–531
   PubMedGoogle Scholar
• Gaetani G F, Ferraris A M, Rolfo M, Mangerini R, Arena S, Kirkman H N. Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood 1996; 87: 1595–1599
   PubMed Web of Science ®Google Scholar
• Mao X, Stewart A K, Hurren R, Datti A, Zhu X, Zhu Y, et al. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood 2007; 110: 4047–4054
   PubMed Web of Science ®Google Scholar
• Margoliash E, Novogrodsky A, Schejter A. Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase. Biochem J 1960; 74: 339–348
   PubMed Web of Science ®Google Scholar
• Tephly T R, Mannering G J, Parks R E, Jr. Studies on the mechanism of inhibition of liver and erythrocyte catalase activity by 3-amino-1,2,4-triazole (AT). J Pharmacol Exp Ther 1961; 134: 77–82
   PubMed Web of Science ®Google Scholar
• Leslie E M, Haimeur A, Waalkes M P. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 2004; 279: 32700–32708
   PubMed Web of Science ®Google Scholar
• Chen G Q, Zhu J, Shi X G, Ni J H, Zhong H J, Si G Y, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052–1061
   PubMed Web of Science ®Google Scholar
• Jing Y, Dai J, Chalmers-Redman R M, Tatton W G, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102–2111
   PubMed Web of Science ®Google Scholar
• Yi J, Yang J, He R, Gao F, Sang H, Tang X, et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004; 64: 108–116
   PubMed Web of Science ®Google Scholar
• Sturlan S, Baumgartner M, Roth E, Bachleitner-Hofmann T. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 2003; 101: 4990–4997
   PubMed Web of Science ®Google Scholar
• Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?. Br J Haematol 2001; 112: 783–786
   PubMed Web of Science ®Google Scholar